KOSDAQBiotech & Pharma222110

Pangen Biotech

₩3,970▲ 0.63%2026-11-18 close
Market Cap
₩53.7B
Turnover
₩6,470,510
Volume
1.6K
Shares out.
13.5M
PER
267.0×
PBR
1.8×
EPS
₩15
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Pangen: EPO export growth alongside quarterly losses

Pangen's revenue has risen for three consecutive quarters from Q1 2026 to Q3 2026 on EPO biosimilar exports, but operating losses in Q2 and Q3 2026 have left its quarterly profit trend mixed.

  1. 1

    Annual revenue peaked at KRW 14.7 billion in 2024 and fell 8.6% to KRW 13.4 billion in 2025.

  2. 2

    Operating profit turned positive in 2024 and reached KRW 1.51 billion in 2025, a 47.6% increase, with an operating margin of 11.2%.

  3. 3

    Operating losses continued in Q2 and Q3 2026. The company attributed the Q3 loss to a raw material defect that halted production and to disposal costs, and the Q2 loss to R&D spending and equipment investment for European entry.

  4. 4

    EPO products are licensed in eight countries. According to company announcements, cumulative EPO sales through Q3 2026 reached KRW 9.38 billion, up 54.4% year on year, and EPO products accounted for about KRW 4 billion of the KRW 7.7 billion backlog at end-June 2026.

  5. 5

    Over the latest four quarters (Q4 2025 to Q3 2026), cumulative net income attributable to controlling shareholders was KRW 230 million, so valuation multiples are highly sensitive to small changes in earnings.

02

Business structure

Pangen Biotech is a biopharmaceutical subsidiary of the Huons Group that runs two businesses built on its cell line development technology and production process know-how. The first is manufacturing and sales of erythropoietin (EPO) biosimilars, and the second is contract development and manufacturing (CDMO).

According to press reports, EPO product sales were KRW 7.5 billion of 2025 revenue of KRW 13.4 billion. The EPO biosimilar received its first product license in Malaysia at the end of 2019 and is now sold in eight countries.

Main markets are the ASEAN countries, including Malaysia, the Philippines and Thailand, and supply has expanded to the Middle East, including Saudi Arabia and Türkiye.

In CDMO, the company holds 41 production cell lines built on its PanGen CHO-TECH platform, comprising 28 for therapeutic proteins and 13 for antibody biosimilars. It has concluded multiple technology transfer agreements and receives technology fees, which the company expects to rise as partners' sales grow.

Its antibody biosimilar pipeline has seven candidates: ipilimumab, guselkumab, romosozumab, pembrolizumab, benralizumab, risankizumab and mepolizumab. Four of these, namely ipilimumab, guselkumab, romosozumab and pembrolizumab, have completed cell line development and are in process development.

Against larger CDMO and biosimilar players in the same sector such as Samsung Biologics and Celltrion, the company is considerably smaller in production scale and global distribution. Its heavy reliance on EPO within total sales is a defining feature of the business structure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4B₩400M9.4%
2025Q4₩2.5B-₩400M−16.3%
2026Q1₩3.7B₩500M12.9%
2026Q2₩4B-₩200M−5.6%
2026Q3₩4B-₩74,811,184−1.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩6.5B-₩4.6B-₩4.5B−70.6%−26.1%20.1%
2023₩7.3B-₩4.2B-₩4.5B−57.8%−35.7%65.1%
2024₩14.7B₩1B₩900M7.0%3.8%22.6%
2025₩13.4B₩1.5B₩2.1B11.2%6.9%9.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue rose from KRW 6.5 billion in 2022 to KRW 14.7 billion in 2024, an increase of 100.6% year on year, and then fell 8.6% to KRW 13.4 billion in 2025. The largest year in 2022–2025 was 2024.

Operating losses of KRW 4.59 billion in 2022 and KRW 4.23 billion in 2023 gave way to an operating profit of KRW 1.02 billion in 2024, which turned the business profitable, and rose to KRW 1.51 billion in 2025, a 47.6% increase. The operating margin improved from -70.6% in 2022 and -57.8% in 2023 to 11.2% in 2025.

Net income attributable to controlling shareholders grew from KRW 944 million in 2024 to KRW 2.05 billion in 2025, a 117.3% increase, and net income including non-controlling interests was also reported at KRW 2.05 billion for 2025.

According to press reports, the 2025 profit improvement reflected both higher EPO exports and higher CDMO revenue. Operating cash flow, however, fell from KRW 2.99 billion in 2024 to KRW 190 million in 2025.

Quarterly, Q3 2025 revenue of KRW 4.01 billion and operating profit of KRW 377 million were followed by Q4 2025 revenue of KRW 2.48 billion, a 38.3% quarter-on-quarter decline, and an operating loss of KRW 404 million, which turned the quarter loss-making.

Q1 2026 revenue of KRW 3.73 billion, up 50.6% from the prior quarter, and an operating profit of KRW 482 million restored profitability.

Q2 2026 revenue rose to KRW 3.96 billion, but an operating loss of KRW 220 million turned the quarter loss-making, and press reports attributed this to higher R&D spending and one-off equipment investment for European market entry.

Q3 2026 revenue of KRW 3.97 billion rose 0.4% from the prior quarter but fell 1.0% year on year, and an operating loss of KRW 74.81 million turned the quarter loss-making compared with a year earlier.

The company said the loss reflected a production halt caused by a raw material defect and related disposal costs, and that the issue did not stem from its own process.

Net loss attributable to controlling shareholders in Q3 2026 was KRW 370 million, and cumulative net income attributable to controlling shareholders over the latest four quarters was KRW 230 million.

05

Industry analysis

In the biosimilar market that Pangen operates in, the number of licensed countries and local distribution networks tend to determine revenue.

Pangen's EPO biosimilar has expanded from its first license in Malaysia at the end of 2019 to sales in eight countries, and that expansion is the key variable behind export growth.

Demand has opened first in Southeast Asia and the Middle East, and the company has named Latin America and Africa as its next target regions.

On competition, Samsung Biologics and Celltrion are counted among same-sector players with large production capacity and global distribution, and Pangen is considerably smaller in production scale.

In CDMO, the company has chosen to develop biosimilars requested by bio ventures and pharmaceutical companies, supported by its 41 cell lines and its record of technology transfers.

Biosimilar development passes through cell line development, process development, licensing and GMP inspection, so revenue tends to rise in steps as development progresses and licenses expand. Production stability depends heavily on raw material quality, as the production halt in Q3 2026 illustrated.

European entry is still at the preparation stage, requiring EU regulatory compliance and GMP inspection, so the timing of any revenue contribution is a variable to be assessed separately.

06

Outlook

The company has said it will pursue new contract development and manufacturing (CDMO) agreements in the second half of 2026. The agreement was initially targeted for signing in Q2 2026 in the company's Q1 announcement, but the Q2 announcement shifted the timing to the second half.

For EPO products, the company plans to strengthen overseas marketing in the second half and to widen export regions to the Middle East, South America and Africa.

The order backlog rose from KRW 5.2 billion at end-March 2026, of which KRW 4.8 billion was EPO, to KRW 7.7 billion at end-June 2026, of which about KRW 4 billion was EPO, so non-EPO orders increased from roughly KRW 0.4 billion to roughly KRW 3.7 billion.

Among the seven antibody biosimilars, ipilimumab, guselkumab and romosozumab are targeted to complete process development within 2026. Benralizumab, risankizumab and mepolizumab are at the cell line development stage.

European entry is at the stage of gap analysis with a European consulting firm, review of EU qualified person requirements, and preparation of equipment replacement and GMP inspection. The related equipment investment was recorded as a one-off cost in Q2 2026 operating results.

The company's position is that continued CDMO contract signings and rising EPO exports would sustain revenue growth. The next checkpoints are completion of process development within 2026 and whether the CDMO agreement is signed in the second half.

07

Valuation

PER
267.0×
PBR
1.8×
ROE
0.8%
EPS
₩15
BPS
₩2,282
Dividend per share
₩0

The current share price multiple depends largely on the scale of earnings.

Net income attributable to controlling shareholders rose to KRW 2.05 billion in 2025 from KRW 944 million in 2024, but cumulative net income over the latest four quarters was only KRW 230 million, so earnings-based multiples can be read in many ways.

The operating losses and net losses attributable to controlling shareholders in Q2 and Q3 2026 also affect how earnings-based multiples should be read. Measured against the equity of KRW 29.9 billion at end-2025, the price-to-book level sits in a range carrying a premium over net assets.

The debt burden is low, with a debt-to-equity ratio of 9.3% at end-2025, so the discussion of valuation centers more on earnings scale than on the capital structure. The dividend yield is low, so shareholder return plays a small role.

The improvement in operating margin from -70.6% in 2022 to 11.2% in 2025 shows a directional change in the business, but with quarterly results alternating between profit and loss, the stability of the multiple is low.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Expanding EPO export footprint

The company has expanded its EPO biosimilar licenses to eight countries and said first-half 2026 EPO sales rose 40% year on year. In its Q3 announcement, the company stated that cumulative EPO sales reached KRW 9.38 billion, up 54.4%.

Supply to the Middle East, including Saudi Arabia and Türkiye, has begun in earnest, and Latin America and Africa have been named as the next export regions. Roughly KRW 4 billion of the KRW 7.7 billion backlog at end-June 2026 was EPO products, which is cited as a basis for predictable overseas demand.

Directional shift in operating margin

Operating margin was -70.6% in 2022 and -57.8% in 2023, but improved to 7.0% in 2024 and 11.2% in 2025. Operating profit reached KRW 1.51 billion in 2025, up 47.6%, and net income attributable to controlling shareholders grew 117.3% to KRW 2.05 billion.

The debt-to-equity ratio at end-2025 was 9.3%, lower than 20.1% in 2022. The case on this side rests on the earnings base built after the shift from a loss-making to a profitable structure.

Technology transfer and pipeline base

The company holds 41 production cell lines, comprising 28 for therapeutic proteins and 13 for antibody biosimilars. It has signed multiple technology transfer agreements based on its proprietary technology and receives technology fees, which the company expects to grow as partners' sales increase.

Among the seven antibody biosimilars, ipilimumab, guselkumab and romosozumab are targeted to complete process development within 2026. The case on this side is that as candidates move from development to commercialization, revenue could diversify beyond EPO.

09

Bear factors

Renewed quarterly losses

Following an operating loss of KRW 220 million in Q2 2026, Q3 2026 posted an operating loss of KRW 74.81 million, making two consecutive loss-making quarters. Net loss attributable to controlling shareholders in Q3 was KRW 370 million, a swing from a profit a year earlier.

The case on this side points to the return of losses after the profitable Q1 2026. Cumulative net income attributable to controlling shareholders over the latest four quarters was only KRW 230 million, which is cited as a thin earnings base.

Raw material quality and capex burden

In Q3 2026, a defect in externally sourced raw materials halted production temporarily, and disposal costs were recorded. The company said the problem did not stem from its own manufacturing process or technical defects.

In Q2 2026, higher R&D spending, one-off equipment investment for European entry and lower plant utilization increased the cost burden. Apart from the company's explanation that these were one-off factors, raw material quality and the timing of capital spending remain variables that can move quarterly results.

EPO concentration and delayed contract timing

Revenue fell 8.6% in 2025, and Q4 2025 revenue of KRW 2.48 billion marked the low point of the last five quarters. EPO accounted for about KRW 4 billion of the KRW 7.7 billion backlog at end-June 2026, so dependence on EPO remains high.

The new CDMO contract was targeted for signing in Q2 2026 in the Q1 announcement, but the Q2 announcement moved it to the second half. The delay in contract timing is cited as a point on the bear side.

10

Risk factors

Production and quality risk

A quality defect in externally sourced raw materials led to a production halt and disposal costs in Q3 2026. Because biopharmaceutical output depends on the stability of cell lines and processes, supplier management is a source of quarterly earnings volatility.

The company described this event as one-off, but a repeat could have a larger impact on results. Quality standards are likely to tighten as the company prepares for GMP inspection for European entry.

Market and regulatory concentration risk

EPO sales are concentrated in Southeast Asian countries such as Malaysia, the Philippines and Thailand, and in Middle Eastern countries such as Saudi Arabia and Türkiye.

Sales depend on country-level licenses and local distribution partners, so regulatory or distribution changes in a given country can directly affect revenue. European entry requires meeting EU qualified person requirements and passing GMP inspection, so timing could slip. If overseas expansion does not proceed as planned, the pace of revenue growth could slow.

Earnings scale and cash flow risk

The balance sheet is relatively light, with a debt-to-equity ratio of 9.3% and total liabilities of KRW 2.78 billion at end-2025. However, operating cash flow fell from KRW 2.99 billion in 2024 to KRW 190 million in 2025.

Cumulative net income over the latest four quarters was only KRW 230 million, so concentrated costs in a single quarter can easily lead to a quarterly loss. Because the earnings base is small, swings in revenue over one or two quarters are reflected strongly in margins.

11

What to watch next

  1. Within 2026 (by end-December)

    Whether process development is completed for ipilimumab, guselkumab and romosozumab. This indicates whether commercialization preparation has advanced a stage.

  2. Second half of 2026

    Whether the new CDMO contract is signed. The target moved from Q2 in the Q1 announcement to the second half in the Q2 announcement, so the timing and scale of the contract are key indicators of a change in revenue structure.

  3. By end-March 2027

    Filing of the 2026 annual report. Full-year 2026 revenue, operating margin and net income attributable to controlling shareholders, including Q4 2026, will be confirmed, showing how the quarterly losses were reflected for the full year.

  4. Around mid-May 2027

    Announcement of Q1 2027 results. Q1 2026 results were announced on May 14, so a similar timing is expected. This is the point to check whether operating results remain in a loss after Q3 2026 and whether EPO export growth is sustained.

12

Overall view

Pangen expanded EPO biosimilar exports, turned profitable in 2024 and raised operating profit again in 2025, with the operating margin improving from -70.6% in 2022 to 11.2% in 2025. After a profitable Q1 2026, operating losses continued in Q2 and Q3 2026, so the quarterly earnings trend is mixed.

The Q3 loss was attributed to a production halt and disposal costs, and the Q2 loss mainly to R&D spending and equipment investment. Bullish factors include the expansion of EPO export countries, a larger order backlog and a pipeline of 41 cell lines and seven biosimilar candidates.

Bearish factors include the return of quarterly losses, a small earnings base and high dependence on EPO products. The balance sheet is relatively light, with a debt-to-equity ratio of 9.3% at end-2025, but operating cash flow fell to KRW 190 million in 2025.

Valuation interpretation is sensitive to the earnings scale, with cumulative net income over the latest four quarters at KRW 230 million. The next checkpoints are completion of process development within 2026, signing of the second-half CDMO contract and the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. pinpointnews.co.kr
  2. thefairnews.co.kr
  3. iminju.net
  4. news1.kr
  5. news.nate.com
  6. thebionews.net
  7. m.news.nate.com
  8. weekly.hankooki.com
  9. m.news.nate.com
  10. seoul.co.kr
  11. kpanews.co.kr
  12. m.news.nate.com
  13. kyungjeilbo.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. newspim.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis